In this presentation from Lymphoma & Myeloma 2016, Dr. C. Ola Landgren provides an update on new approaches and the clinical value of assessing minimal residual disease in myeloma.
Earn CME credit for a related activity at the following location:
http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225
© 2016 Imedex, LLC.
Advertisement